Compare Merck & Co., Inc. (MRK) vs Target Corporation (TGT) Price & Performance

Merck & Co., Inc.Trade

Target CorporationTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Target Corporation — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while Target Corporation trades at $138.64 (market cap $63.40B). The key difference: Merck & Co., Inc. is far larger — about 4.8× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.32%). Which is the better fit depends on your goals.

	MRK	TGT
Market Cap	$307.25B	$63.40B
Sector	Health	Consumer Cyclical
52-Week High	$129.52	$141.19
52-Week Low	$77.60	$83.68
Enterprise Value	$350.66B	$78.70B
Dividend Yield	2.73%	3.32%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Target Corporation

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

TGT

Target launches exclusive baby collection and gets a 'Buy' rating with a $150 price target.Stuart Mooney · 1 day agoBullish Target launches Picolette, a stylish and affordable baby collection by Olivia Culpo.PRNewsWire · 1 day agoBullish Target recalls 211,000 toddler sandals over choking hazard from loose decorative pearlsNew York Post · 4 days agoBearish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Target Corporation

With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.